PRGONYSEPharmaceutical PreparationsFiscal year ends December 31

PERRIGO Co plc

Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 5, 2026

$16.09−0.54 (-3.25%)

Close on Oct 19, 2026

Market cap: $2.25B
P/E (TTM): –
Dividend yield: 7.21%

Debt

Borrowings on the balance sheet, Jun 27, 2026

Total debt

$3.29B

$11.40M due within a year

Net debt

$2.90B

After $399.70M of cash

Implied interest rate

–

FY2025 interest ÷ average debt

Interest coverage

–

FY2025 operating income ÷ interest

Total debt by fiscal year

Long-term plus current debt, USD

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Perrigo's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Perrigo's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on Aug 26, 1993
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PRGO.

Revenue growth-4.2% · median 4.4%

Gross margin33.3% · median 52.7%

Operating margin-37.7% · median 10.3%

Net margin-41.9% · median 4.4%

Company	Revenue	Growth
VTRS	$14.74B	+4.4%
OGN	$6.13B	-2.5%
PRGO	$4.14B	-4.2%
AMRX	$3.12B	+9.3%
PBH	$1.10B	-1.4%
NATR	$492.02M	+6.8%

Company

Next earnings (est.): Nov 4, 2026, before open
Exchange: NYSE
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 8,100
Held by institutions: 100.0%
Auditor: Ernst & Young LLP
SEC CIK: 1585364

Advertisement
300 × 250